Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Next Previous
X
Search
Trial Profile

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acarbose (Primary) ; Benazepril (Primary) ; Candesartan cilexetil (Primary) ; Carvedilol (Primary) ; Chlortalidone (Primary) ; Diltiazem (Primary) ; Exenatide (Primary) ; Felodipine (Primary) ; Fenofibrate (Primary) ; Hydralazine (Primary) ; Hydrochlorothiazide/metoprolol (Primary) ; Lisinopril/hydrochlorothiazide (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Repaglinide (Primary) ; Reserpine (Primary) ; Terazosin (Primary) ; Valsartan (Primary) ; Valsartan/hydrochlorothiazide (Primary) ; ACE inhibitors; Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Alpha-glucosidase inhibitors; Amlodipine/benazepril; Angiotensin receptor antagonists; Antihyperglycaemics; Antihypertensives; Beta adrenergic receptor antagonists; Calcium channel antagonists; Cardiovascular therapies; Exenatide; Glimepiride; HMG-CoA reductase inhibitors; Insulin; Insulin aspart; Insulin detemir; Insulin glargine; Insulin suspension isophane; Insulins; Rosiglitazone; Simvastatin; Thiazide diuretics
  • Indications Alzheimer's disease; Cardiovascular disorders; Dementia; Diabetic angiopathies; Diabetic complications; Diabetic retinopathy; Hypercholesterolaemia; Hypertension; Myocardial infarction; Stroke; Type 2 diabetes mellitus; Vascular dementia
  • Focus Therapeutic Use
  • Acronyms ACCORD; ACCORD-BONE; ACCORD-BP; ACCORD-EYE; ACCORD-LIPID; ACCORD-MIND

    • Most Recent Events

    • 01 Sep 2024 Results published in the Endocrine
    • 16 Sep 2023 Results of secondary analysis evaluating disparities in achieving diabetes treatment targets by race/ethnicity and educational attainment within this study, published in the Diabetologia
    • 01 Mar 2023 Results (n=10132) evaluating the longitudinal relationships between VAI and incident nephropathy outcomes in T2DM patients. published in the Diabetes/Metabolism Research and Reviews

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top